Cochrane · systematic review · CD003280
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy
Mahdi‐Rogers, M, Brassington, R, Gunn, AA, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyMethotrexate compared to placebo for CIDP
Population: people with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants able to reduce corticosteroid or IVIg dose by more than 20% Methotrexate vs placebo | RR 1.21 [0.4, 3.7] | 1 study · 59 participants | Moderate |
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. Methotrexate vs placebo | no estimate extracted | 1 study · 59 participants | Low |
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. Methotrexate vs placebo | no estimate extracted | 1 study · 59 participants | Low |
Serious adverse events Methotrexate vs placebo | RR 3.56 [0.39, 32.23] | 1 study · 59 participants | Moderate |
Interferon beta‐1a compared to placebo for CIDP
Population: people with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in disability after 26 or more weeks Interferon beta‐1a vs placebo | no estimate extracted | NR | No studies |
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal Interferon beta‐1a vs placebo | RR 1 [0.54, 1.88] | 1 study · 49 participants | Moderate |
Serious adverse events Interferon beta‐1a vs placebo | RR 4.5 [0.25, 80.05] | 1 study · 67 participants | Low |
Methotrexate compared to placebo for CIDP
Population: patients with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants able to reduce corticosteroid or IVIg dose by more than 20% Methotrexate vs placebo | RR 1.21 [0.4, 3.7] | 1 study · 59 participants | Moderate |
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. Methotrexate vs placebo | no estimate extracted | 1 study · 59 participants | Low |
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. Methotrexate vs placebo | no estimate extracted | 1 study · 59 participants | Low |
Serious adverse events Methotrexate vs placebo | RR 3.56 [0.39, 32.23] | 1 study · 59 participants | High |
Interferon beta‐1a compared to placebo for CIDP
Population: CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal Interferon beta‐1a vs placebo | RR 1 [0.54, 1.88] | 1 study · 49 participants | Moderate |
Serious adverse events Interferon beta‐1a vs placebo | RR 4.5 [0.25, 80.05] | 1 study · 67 participants | High |
Methotrexate compared to placebo for CIDP
Population: patients with CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants able to reduce corticosteroid or IVIg dose by more than 20% Methotrexate vs placebo | RR 1.21 [0.4, 3.7] | 1 study · 59 participants | Moderate |
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. Methotrexate vs placebo | no estimate extracted | 1 study · 59 participants | Low |
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. Methotrexate vs placebo | no estimate extracted | 1 study · 59 participants | Low |
Serious adverse events Methotrexate vs placebo | RR 3.56 [0.39, 32.23] | 1 study · 59 participants | High |
Interferon beta‐1a compared to placebo for CIDP
Population: CIDP
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal Interferon beta‐1a vs placebo | RR 1 [0.54, 1.88] | 1 study · 49 participants | Moderate |
Serious adverse events Interferon beta‐1a vs placebo | RR 4.5 [0.25, 80.05] | 1 study · 67 participants | High |